Shanshan Jiang
Research Subjects
Shanshan Jiang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Yue Zou
R&D Center, Shanghai CHANDO Group Co., Ltd., Shanghai 200233, China
2 shared publications - Audrey Le Mestr
Ashland Specialties France, Affiliate of Ashland Inc., 06904 Sophia Antipolis, France
1 shared publication - Catherine Serre
Ashland Specialties France, Affiliate of Ashland Inc., 06904 Sophia Antipolis, France
1 shared publication - Fenglou Wang
R&D Center, Shanghai CHANDO Group Co., Ltd., Shanghai 200233, China
1 shared publication - Gang Ma
Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Bio-X Institutes, Shanghai Jiao Tong University, Shanghai 200240, China
1 shared publication - Hui Ren
R&D Center, Shanghai CHANDO Group Co., Ltd., Shanghai 200233, China
1 shared publication
Latest Publications
- Open Access
Plant Small RNA-Rich Himalayan Anethum graveolens Extract Modulates Aging-Associated microRNA Signatures to Enhance Dermal Architecture Protein Synthesis in Human Skin
In December 2024, scientists Victor Ambros and Gary Ruvkun were awarded the Nobel Prize in Physiology or Medicine for their novel discovery of post-transcriptional gene regulation via microRNA (miRNA). This large class of non-coding RNAs defines a new layer of gene regulation activity that can control many biological processes in multicellular organisms. This experimental study explores how Himalayan Anethum graveolens extract (HAGE), rich in small RNAs, obtained by PSR technology™, can modulate human miRNAs and skin signaling pathways to improve dermal architecture and elastic fiber integrity for anti-aging benefits. Our epigenomic study analyzes skin biopsies from Chinese individuals according to different characteristics (chronological age, photoprotection…) and identifies distinct miRNA expression profiles associated with both endogenous and exogenous aging pathways using analytical and bioinformatics methodologies. Differential targeting of aging-related genes suggests that specific miRNAs may play a regulatory role in coordinating these two aging processes. Our in vitro experiments in normal human dermal fibroblasts indicate that 0.05% HAGE decreased the expression of miRNA signatures associated with intrinsic aging (miR-30c-2-3p and miR-125b-1-3p) and photoaging (miR-16-2-3p). Further in vitro and ex vivo assays, with the ex vivo findings to be regarded as preliminary, also showed increases in dermal matrix proteins such as collagen type I and III, elastin, fibrillin-1 and dermatopontin. We demonstrated that HAGE decreases key aging-associated miRNAs, including miR-30c-2-3p and miR-125b-1-3p (intrinsic aging) and miR-16-2-3p (photoaging). IGF1 and IGF1R are established miRNA targets, identified as skin endogenous aging target genes of miR-30c-2-3p and miR-125b-1-3p (invention patent ZL201810165800.7, IDP000089683) and are involved in cell growth and renewal, whereas CTGF (CCN2) is an experimentally supported target of miR-16-2-3p; however, the restoration of these target axes by HAGE was not directly measured. In ex vivo and in vitro models, HAGE increased collagen type I and III, elastin, fibrillin-1 and dermatopontin, supporting its potential regulatory impact on skin aging mechanisms. Our experiments are consistent with an epigenetic modulation model of aging prevention based on the modulation of miRNAs as aging gene-silencing agents by topical application of extracts rich in small RNAs such as HAGE. Whether plant small RNAs are taken up by and functional in human skin cells, and whether this modulation translates into clinical anti-aging benefits remains to be established.
Open AccessPlant Small RNA-Rich Himalayan Anethum graveolens Extract Modulates Aging-Associated microRNA Signatures to Enhance Dermal Architecture Protein Synthesis in Human Skin
In December 2024, scientists Victor Ambros and Gary Ruvkun were awarded the Nobel Prize in Physiology or Medicine for their novel discovery of post-transcriptional gene regulation via microRNA (miRNA). This large class of non-coding RNAs defines a new layer of gene regulation activity that can control many biological processes in multicellular organisms. This experimental study explores how Himalayan Anethum graveolens extract (HAGE), rich in small RNAs, obtained by PSR technology™, can modulate human miRNAs and skin signaling pathways to improve dermal architecture and elastic fiber integrity for anti-aging benefits. Our epigenomic study analyzes skin biopsies from Chinese individuals according to different characteristics (chronological age, photoprotection…) and identifies distinct miRNA expression profiles associated with both endogenous and exogenous aging pathways using analytical and bioinformatics methodologies. Differential targeting of aging-related genes suggests that specific miRNAs may play a regulatory role in coordinating these two aging processes. Our in vitro experiments in normal human dermal fibroblasts indicate that 0.05% HAGE decreased the expression of miRNA signatures associated with intrinsic aging (miR-30c-2-3p and miR-125b-1-3p) and photoaging (miR-16-2-3p). Further in vitro and ex vivo assays, with the ex vivo findings to be regarded as preliminary, also showed increases in dermal matrix proteins such as collagen type I and III, elastin, fibrillin-1 and dermatopontin. We demonstrated that HAGE decreases key aging-associated miRNAs, including miR-30c-2-3p and miR-125b-1-3p (intrinsic aging) and miR-16-2-3p (photoaging). IGF1 and IGF1R are established miRNA targets, identified as skin endogenous aging target genes of miR-30c-2-3p and miR-125b-1-3p (invention patent ZL201810165800.7, IDP000089683) and are involved in cell growth and renewal, whereas CTGF (CCN2) is an experimentally supported target of miR-16-2-3p; however, the restoration of these target axes by HAGE was not directly measured. In ex vivo and in vitro models, HAGE increased collagen type I and III, elastin, fibrillin-1 and dermatopontin, supporting its potential regulatory impact on skin aging mechanisms. Our experiments are consistent with an epigenetic modulation model of aging prevention based on the modulation of miRNAs as aging gene-silencing agents by topical application of extracts rich in small RNAs such as HAGE. Whether plant small RNAs are taken up by and functional in human skin cells, and whether this modulation translates into clinical anti-aging benefits remains to be established.
- Open Access
- 22 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2584
Terminalia chebula Retz. Fruit Extract Promotes Murine Hair Growth by Suppressing 5α-Reductase and Accelerating the Degradation of Dihydrotestosterone
Background/Objectives: Androgenetic alopecia (AGA) is the most common hair loss disorder in dermatological practice. Its primary pathogenesis involves the conversion of testosterone to dihydrotestosterone (DHT) by type II 5α-reductase upon reaching dermal papilla cells (DPCs). DHT impairs DPCs’ activity and inhibits hair growth. Although the FDA-approved drugs finasteride and minoxidil show certain efficacy, they are also associated with severe side effects. This study aims to explore the effects of Terminalia chebula fruit extract (TCFE) on hair growth and its underlying molecular mechanisms. Methods: We investigated the therapeutic potential of TCFE in hair follicle regeneration, employing a multi-level experimental approach combining in vitro analyses of DPCs, in vivo animal models of AGA, and ex vivo cultures of human hair follicles and scalp tissue. Results: First, RNA-seq analysis and RT-PCR validation revealed that TCFE treatment activated the Wnt and TGF-β3 signaling pathways in DPCs, particularly upregulating the AKR1C gene family, which is involved in DHT metabolism. TCFE also potently inhibited type II 5α-reductase activity and mitigated DHT-induced damage to DPCs. In an AGA mouse model, TCFE reversed the AGA phenotype with efficacy comparable to finasteride. However, unlike finasteride, TCFE specifically enhanced the expression of AKR1C1 and AKR1C3, indicating a distinct mechanism. Finally, in ex vivo organ cultures, TCFE suppressed hair follicle cell apoptosis, promoted proliferation, and thereby stimulated hair growth. Conclusions: These findings suggest that TCFE is a promising natural treatment for AGA, likely acting through multiple mechanisms, including Wnt pathway activation, 5α-reductase inhibition, and enhanced DHT degradation.
- 22 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2584
Open AccessTerminalia chebula Retz. Fruit Extract Promotes Murine Hair Growth by Suppressing 5α-Reductase and Accelerating the Degradation of Dihydrotestosterone
Background/Objectives: Androgenetic alopecia (AGA) is the most common hair loss disorder in dermatological practice. Its primary pathogenesis involves the conversion of testosterone to dihydrotestosterone (DHT) by type II 5α-reductase upon reaching dermal papilla cells (DPCs). DHT impairs DPCs’ activity and inhibits hair growth. Although the FDA-approved drugs finasteride and minoxidil show certain efficacy, they are also associated with severe side effects. This study aims to explore the effects of Terminalia chebula fruit extract (TCFE) on hair growth and its underlying molecular mechanisms. Methods: We investigated the therapeutic potential of TCFE in hair follicle regeneration, employing a multi-level experimental approach combining in vitro analyses of DPCs, in vivo animal models of AGA, and ex vivo cultures of human hair follicles and scalp tissue. Results: First, RNA-seq analysis and RT-PCR validation revealed that TCFE treatment activated the Wnt and TGF-β3 signaling pathways in DPCs, particularly upregulating the AKR1C gene family, which is involved in DHT metabolism. TCFE also potently inhibited type II 5α-reductase activity and mitigated DHT-induced damage to DPCs. In an AGA mouse model, TCFE reversed the AGA phenotype with efficacy comparable to finasteride. However, unlike finasteride, TCFE specifically enhanced the expression of AKR1C1 and AKR1C3, indicating a distinct mechanism. Finally, in ex vivo organ cultures, TCFE suppressed hair follicle cell apoptosis, promoted proliferation, and thereby stimulated hair growth. Conclusions: These findings suggest that TCFE is a promising natural treatment for AGA, likely acting through multiple mechanisms, including Wnt pathway activation, 5α-reductase inhibition, and enhanced DHT degradation.